How GLP-1 Drugs Are Reshaping the Food and Beverage Industry

GLP-1 drugs such as Ozempic and Wegovy are changing not only how people lose weight but also what they eat and drink. These medications suppress appetite and alter food cravings, leading to a drop in calorie intake and a shift away from sugary, fatty products. According to a report from FTI Consulting, this transformation is forcing food and beverage companies to rethink their product lines, packaging, and marketing strategies.

The shift is bigger than a single diet trend. When a medication quietly rewires how a large slice of the population responds to a candy bar, a soda, or a second helping, the effect ripples all the way back to the factory. Ingredient buyers, package designers, shelf planners, and restaurant menu teams are all watching the same question: if millions of shoppers simply stop wanting the products that built these companies, what replaces that revenue? This article walks through what the medications actually do to appetite, which food categories are most exposed, how manufacturers are already reformulating, and what it means for you if you are the one taking the drug.

Key takeaways

• GLP-1 drugs reduce overall food consumption and change taste preferences, often flattening the pull of sugar, alcohol, and ultra-processed snacks.
• Food and beverage companies are reformulating products, adding protein and fiber, and shrinking portions to appeal to users of these medications.
• Portion sizes and packaging formats are being adapted for smaller appetites, and marketing is pivoting from indulgence to satiety.
• Confectionery, sugary drinks, salty snacks, and alcohol face the most exposure, while high-protein and functional products stand to gain.
• The long-term impact on food industry revenue could be significant if GLP-1 use becomes widespread.

Consumer appetite changes on GLP-1 drugs

Users of GLP-1 receptor agonists often report eating less food overall, with a marked decrease in cravings for high-calorie items like sweets, fried snacks, and sugary drinks. The FTI Consulting analysis notes that these drugs slow gastric emptying, which makes people feel full longer. As a result, total daily calorie intake can drop by 20 to 30 percent. Beverages, especially those with added sugar, are often among the first items cut from the diet.

Many users describe the change less as willpower and more as the disappearance of what they call food noise, the constant background chatter that pushes a person toward the pantry between meals. When that noise goes quiet, the snack aisle simply stops calling. This is a key point for food companies, because a large share of packaged food revenue comes from impulse and habit rather than hunger. A shopper who no longer feels the tug at 3 p.m. does not reach for the vending machine, and that missing reach shows up in the numbers.

The categories hit first tend to be the ones tied most tightly to reward rather than nutrition. Sugary sodas and energy drinks are early casualties, followed by candy, pastries, chips, and ice cream. Alcohol is another quiet loser, because the same brain pathways that dampen the appeal of sugar also seem to reduce the desire for a drink. Meat-heavy fast food loses some ground too, though lean protein often survives the shift because users are told to prioritize it.

This behavioral change is not limited to current users. The report suggests that as awareness of GLP-1 drugs grows, even people not taking them may alter their eating habits, anticipating a future shift in the market. Households that share a kitchen with a GLP-1 user often change what they buy as a group, which multiplies the effect beyond the individual prescription.

Why cravings actually change

To understand why the food industry is reacting so strongly, it helps to know what these drugs do inside the body. GLP-1, or glucagon-like peptide-1, is a hormone the gut releases naturally after you eat. It tells the pancreas to release insulin, tells the stomach to empty more slowly, and signals the brain that you are full. The medications are engineered versions of that hormone that last far longer than the natural one, so the fullness signal stays switched on for hours or days rather than minutes.

Two effects matter most for what lands in the shopping cart. First, slower gastric emptying means food sits in the stomach longer, so a small meal feels like a large one and a second helping feels unpleasant. Second, GLP-1 receptors sit in reward-related regions of the brain, which appears to blunt the dopamine hit that sugar, fat, and alcohol normally deliver. The result is not just eating less of the same foods but wanting different foods, with rich and sweet items losing their shine while simpler, protein-forward meals become easier to finish.

There is a flip side that shapes purchases too. Nausea and early fullness push some users toward bland, easy-to-tolerate foods, and slowed digestion raises the risk of constipation, which is why fiber and fluids suddenly matter more. Companies that understand this are not only cutting sugar, they are designing products that sit gently in a sensitive stomach while still delivering the protein and fiber a shrinking appetite can no longer get from volume alone.

How food companies are responding

Major food and beverage manufacturers are already taking notice. Some are launching smaller portion sizes or multipacks designed for lighter eating. Others are reducing sugar, fat, and calorie content in existing products. The FTI Consulting report highlights that companies are also investing in products with higher protein and fiber content, which align with the dietary needs of GLP-1 users who must maintain muscle mass and avoid nutrient deficiencies.

A few strategic patterns are emerging. The first is companion products, whole lines built and labeled specifically for people on the medications, leaning on portion-controlled, protein-dense, nutrient-fortified meals. The second is quiet reformulation, where an existing best seller is nudged toward more protein and fiber and less sugar without a loud relaunch, so the brand keeps its shelf space while adapting to new tastes. The third is repositioning, taking a product that already fits, such as a Greek yogurt or a bean-based snack, and marketing it directly to the GLP-1 shopper.

Marketing messages are evolving too. Instead of emphasizing indulgence or large portions, brands are promoting satiety, protein density, and digestive health. Language like keeps you full, supports lean muscle, and gentle on digestion is replacing the older vocabulary of treat yourself and share size. The report warns that companies slow to adapt may lose market share as consumer preferences shift permanently.

The nutrition gap GLP-1 users have to manage

The same appetite drop that thrills the diet market creates a real nutritional problem, and it is one reason companies are racing to fortify their products. When someone eats 20 to 30 percent less food, they also take in less protein, less fiber, and fewer vitamins and minerals unless every remaining bite is chosen carefully. The biggest risk is muscle. Rapid weight loss of any kind strips away lean tissue along with fat, and losing muscle slows metabolism, weakens the body, and makes the weight easier to regain later.

This is why clinicians who manage GLP-1 patients push protein at every meal, resistance training a few times a week, and often a check on the numbers that sit underneath the scale. Weight on a bathroom scale cannot tell you whether you are losing fat or muscle, whether your blood sugar and insulin are improving, or whether a nutrient like iron, vitamin B12, or vitamin D is drifting low as intake falls. Those answers live in bloodwork, not on the scale, and they are exactly the markers that get overlooked when the only feedback someone tracks is a smaller number in the morning.

For the food industry, this nutrition gap is also the opportunity. Products that deliver 20 or more grams of protein, meaningful fiber, and added micronutrients in a small, easy-to-digest serving fit the exact hole that rapid appetite loss creates. That is why protein shakes, fortified meal replacements, and high-fiber snacks are the categories most often named as winners in a GLP-1 world.

Implications for product development

The FTI Consulting analysis points to new opportunities in the food industry. Meal replacements, ready-to-drink protein shakes, and high-fiber snacks are becoming more popular. Beverage companies are developing low-sugar or sugar-free alternatives with added electrolytes and vitamins. Bakery and confectionery sectors face the biggest challenge, as their core products are often high in refined carbohydrates and sugars that GLP-1 users avoid.

Product teams are also rethinking format, not just recipe. A single-serve protein pot that opens easily, a shake that can be sipped slowly without triggering nausea, or a resealable snack pack that lets a smaller appetite stop after a few bites all respond to how GLP-1 users actually eat. Texture matters more than it used to as well, since some users report that very sweet or very greasy mouthfeel becomes off-putting on the medication. The winning briefs read less like indulgence and more like clinical nutrition dressed as an everyday snack.

Restaurants and fast-food chains are also adjusting. Some are adding smaller meal options or modifying combos to include more vegetables and lean proteins. The report suggests that menu labeling with calorie counts could become more influential as consumers on GLP-1 drugs become more health-conscious. Half-size entrees, build-your-own bowls, and protein-first menu sections give a lighter eater a reason to still walk in the door rather than skip the visit entirely.

Which categories win and which lose

Not every part of the grocery store is exposed the same way. The clearest losers are the categories built on cheap sugar, refined starch, and impulse, because those are precisely the products a quieted appetite stops reaching for. Regular soda and energy drinks, candy and chocolate, cookies and pastries, salty snacks eaten by the handful, and large-format indulgence packs all sit in the danger zone. Alcohol belongs there too, since reduced desire for a drink is one of the more consistent side reports from users.

The likely winners share a profile: high protein, real fiber, controlled portions, and a nutrition story a shopper can read on the front of the pack. Ready-to-drink protein shakes, Greek and skyr-style yogurts, high-protein bars with clean labels, bean and legume snacks, fortified meal replacements, and low-sugar functional beverages with electrolytes and vitamins all fit. Fresh produce and lean proteins sit in a comfortable middle, since a GLP-1 user eating less volume still needs quality in every bite. The uncomfortable truth for legacy brands is that the categories with the fattest historical margins are often the ones most at risk, while the growth sits in products that are harder and more expensive to make well.

How retailers and grocery shelves are shifting

The change does not stop at the manufacturer. Grocery retailers sit closest to the shopper, and they are the first to see a basket quietly shrink. When a regular customer stops adding two sodas, a candy bar, and a family-size bag of chips, the total ring at checkout drops even if the person still shops every week. Retailers respond by giving more shelf space and better placement to the categories that are growing, protein drinks, high-fiber snacks, yogurt, and functional beverages, and by trimming the endcaps and impulse zones that used to move sugary volume.

Private label is a quiet winner here. Store brands can copy a successful protein or fiber format quickly and sell it cheaper, which matters to a shopper who is already paying for medication and wants the nutritional benefit without a premium price tag. Retailers are also rethinking the perimeter of the store, where fresh produce, lean meat, dairy, and prepared high-protein meals live, because that is exactly where a GLP-1 shopper now spends a larger share of a smaller budget. The center aisles full of shelf-stable sugar face the most pressure to justify their footprint.

What this means if you are the one taking the drug

Behind the industry story is a personal one. If you are on a GLP-1 medication, the reformulation trend works in your favor, because it means more products designed to give you protein and fiber without volume you can no longer stomach. But shelves cannot manage your health for you. The practical playbook that clinicians repeat is simple to say and easy to skip: aim for protein at every meal, usually landing somewhere near 25 to 30 grams per sitting depending on your size and your clinician’s guidance, add fiber and fluids to stay ahead of constipation, and lift something heavy a couple of times a week to defend your muscle.

Just as important is knowing whether the drug is doing what you actually want, which is losing fat while your health markers improve, not just losing weight on a scale. That distinction is why the smartest users pair the medication with real medical oversight. A clinician can adjust your dose, check your bloodwork, screen for the deficiencies that appear when intake drops, and confirm that a stalled scale is a plateau rather than a thyroid or hormone issue hiding underneath.

Long-term industry trends

Although GLP-1 drug adoption is still relatively low in the general population, prescription rates are rising quickly. The FTI Consulting report notes that if current trends continue, food companies will need to fundamentally shift their portfolios. Products that rely on high sugar or fat content may see declining sales. Meanwhile, categories like functional foods, protein bars, and hydration drinks could grow. The report emphasizes that food manufacturers should not view this as a temporary fad but as a structural change in the market.

There are open questions that will decide how deep the shift goes. Price and insurance coverage will determine how many people can stay on the drugs long enough to change their habits for good. Newer oral versions could widen access far beyond today’s injectable users. And the durability of the behavior change matters: if people who stop the medication see their old cravings return, some of the lost snack revenue may come back with them. Even so, the direction is clear enough that the companies moving early on protein, fiber, and smaller formats are treating this as the new baseline rather than a passing wave.

Frequently Asked Questions

How do GLP-1 drugs affect appetite and food choices?

GLP-1 receptor agonists work by mimicking a hormone that signals fullness to the brain. They also slow stomach emptying, which reduces appetite and extends the feeling of satiety after eating. Most users report eating smaller portions and losing interest in high-sugar, high-fat foods. Instead, they often crave nutrient-dense options like proteins and vegetables.

Are food companies reformulating products because of GLP-1 drugs?

Yes, many food and beverage companies are already adjusting their products. According to the FTI Consulting report, manufacturers are creating smaller package sizes, reducing sugar and fat content, and adding more protein and fiber. Some are also testing new flavors and textures that appeal to consumers whose taste preferences have changed while taking GLP-1 medications.

Will the impact of GLP-1 drugs on food industry last?

The FTI Consulting report suggests these changes are likely to persist. Rising prescription rates, plus the proven effectiveness of the drugs for weight loss, mean that a growing number of consumers will adopt these eating patterns. Food companies that invest now in reformulation and new product development will be better positioned for long-term success, while those that ignore the trend may lose relevance.

Which food and drink categories are most at risk?

The most exposed categories are those built on sugar, refined starch, and impulse buying. That includes regular soda and energy drinks, candy and chocolate, cookies and pastries, salty snacks, large indulgence packs, and alcohol. These are the products a quieted appetite stops reaching for first, so brands concentrated in these areas face the steepest pressure to reformulate or reposition.

What should someone on a GLP-1 drug prioritize eating?

Because appetite and total intake fall sharply, every bite has to count. Clinicians generally emphasize protein at each meal to protect muscle, fiber and fluids to prevent constipation, and nutrient-dense whole foods over empty calories. Many users lean on protein shakes and fortified meal replacements to hit their protein target when they simply cannot eat much volume. Resistance training and regular bloodwork round out the plan.

Do GLP-1 drugs reduce alcohol and soda consumption too?

Many users report a noticeable drop in the desire for both. The same reward pathways in the brain that make sugar and fat less appealing appear to reduce the pull of alcohol and sweet drinks. Sugary beverages are often among the first items people cut, and lower alcohol interest is one of the more frequently described side effects, which is part of why beverage companies are watching the trend closely.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.